TY - JOUR
T1 - Clinical Outcomes in 3343 Children and Adults with Rheumatic Heart Disease from 14 Low-and Middle-Income Countries
T2 - Two-Year Follow-Up of the Global Rheumatic Heart Disease Registry (the REMEDY Study)
AU - Zühlke, Liesl
AU - Karthikeyan, Ganesan
AU - Engel, Mark E.
AU - Rangarajan, Sumathy
AU - Mackie, Pam
AU - Cupido-Katya Mauff, Blanche
AU - Islam, Shofiqul
AU - Daniels, Rezeen
AU - Francis, Veronica
AU - Ogendo, Stephen
AU - Gitura, Bernard
AU - Mondo, Charles
AU - Okello, Emmy
AU - Lwabi, Peter
AU - Al-Kebsi, Mohammed M.
AU - Hugo-Hamman, Christopher
AU - Sheta, Sahar S.
AU - Haileamlak, Abraham
AU - Daniel, Wandimu
AU - Goshu, Dejuma Yadeta
AU - Abdissa, Senbeta G.
AU - Desta, Araya G.
AU - Shasho, Bekele A.
AU - Begna, Dufera M.
AU - Elsayed, Ahmed
AU - Ibrahim, Ahmed S.
AU - Musuku, John
AU - Bode-Thomas, Fidelia
AU - Yilgwan, Christopher C.
AU - Amusa, Ganiyu A.
AU - Ige, Olukemi
AU - Okeahialam, Basil
AU - Sutton, Christopher
AU - Misra, Rajeev
AU - Abul Fadl, Azza
AU - Kennedy, Neil
AU - Damasceno, Albertino
AU - Sani, Mahmoud U.
AU - Ogah, Okechukwu S.
AU - Elhassan, Taiwo Olunugahuda H.M.
AU - Mocumbi, Ana Olga
AU - Adeoye, Abiodun M.
AU - Mntla, Phindile
AU - Ojji, Dike
AU - Mucumbitsi, Joseph
AU - Teo, Koon
AU - Yusuf, Salim
AU - Mayosi, Bongani M.
N1 - Funding Information:
REMEDY (Global Rheumatic Heart Disease Registry) was funded principally by the Canadian Network and Center for Trials Internationally (CANNeCTIN) program lead by the Population Health Research Institute as part of the Clinical Research Initiative of Canadian Institutes of Health Research (www.cannectin.ca/). The other sources of funding were the South African Medical Research Council, Lily and Ernst Hausmann Trust, the Else Kroner Fresenius Foundation, the University of Cape Town, the National Research Foundation of South Africa, Harold and Ethel Pupkewitz Heart Foundation (Namibia), and the World Heart Federation. The Jos site was funded by the Jos University Teaching Hospital, the Heart Aid Trust Inc., and FaithAlive Foundation. The Sudan sites had partial funding from Sheikan Insurance Company. Drs Blanche Cupido and Liesl Zühlke were funded in part by the Discovery Foundation. Dr Zühlke was also funded by a US National Institutes of Health Fogarty International Clinical Research Fellowship, Thrasher Research Fund Early Career Award, Wellcome Trust Clinical Infectious Disease Research Initiative (CIDRI) Research Officer Award, the Hamilton Naki Clinical Scholarship, and by Medtronic Foundation through support to Rheumatic Heart Disease Action. Dr Salim Yusuf is funded by the Marion Burke Chair of the Heart and Stroke Foundation of Canada. The Namibian site was supported by the Harold and Ethel Pupkewitz Heart Foundation. The funders of this study had no role in its design, data collection, data analysis, data interpretation, writing of the report, or in the decision to submit the paper for publication. Several authors (Drs Mayosi, Zühlke, Karthikeyan, Yusuf, Teo, Islam, and Rangarajan) had full access to all the data in the study, and all authors had final responsibility for the decision to submit for publication.
Publisher Copyright:
© 2016 American Heart Association, Inc.
PY - 2016/11/8
Y1 - 2016/11/8
N2 - Background: There are few contemporary data on the mortality and morbidity associated with rheumatic heart disease or information on their predictors. We report the 2-year follow-up of individuals with rheumatic heart disease from 14 low-and middle-income countries in Africa and Asia. Methods: Between January 2010 and November 2012, we enrolled 3343 patients from 25 centers in 14 countries and followed them for 2 years to assess mortality, congestive heart failure, stroke or transient ischemic attack, recurrent acute rheumatic fever, and infective endocarditis. Results: Vital status at 24 months was known for 2960 (88.5%) patients. Two-thirds were female. Although patients were young (median age, 28 years; interquartile range, 18-40), the 2-year case fatality rate was high (500 deaths, 16.9%). Mortality rate was 116.3/1000 patient-years in the first year and 65.4/1000 patient-years in the second year. Median age at death was 28.7 years. Independent predictors of death were severe valve disease (hazard ratio [HR], 2.36; 95% confidence interval [CI], 1.80-3.11), congestive heart failure (HR, 2.16; 95% CI, 1.70-2.72), New York Heart Association functional class III/IV (HR, 1.67; 95% CI, 1.32-2.10), atrial fibrillation (HR, 1.40; 95% CI, 1.10-1.78), and older age (HR, 1.02; 95% CI, 1.01-1.02 per year increase) at enrollment. Postprimary education (HR, 0.67; 95% CI, 0.54-0.85) and female sex (HR, 0.65; 95% CI, 0.52-0.80) were associated with lower risk of death. Two hundred and four (6.9%) patients had new congestive heart failure (incidence, 38.42/1000 patient-years), 46 (1.6%) had a stroke or transient ischemic attack (8.45/1000 patient-years), 19 (0.6%) had recurrent acute rheumatic fever (3.49/1000 patient-years), and 20 (0.7%) had infective endocarditis (3.65/1000 patient-years). Previous stroke and older age were independent predictors of stroke/transient ischemic attack or systemic embolism. Patients from low-and lower-middle-income countries had significantly higher age-and sex-adjusted mortality than patients from upper-middle-income countries. Valve surgery was significantly more common in upper-middle-income than in lower-middle-or low-income countries. Conclusions: Patients with clinical rheumatic heart disease have high mortality and morbidity despite being young; those from low-and lower-middle-income countries had a poorer prognosis associated with advanced disease and low education. Programs focused on early detection and the treatment of clinical rheumatic heart disease are required to improve outcomes.
AB - Background: There are few contemporary data on the mortality and morbidity associated with rheumatic heart disease or information on their predictors. We report the 2-year follow-up of individuals with rheumatic heart disease from 14 low-and middle-income countries in Africa and Asia. Methods: Between January 2010 and November 2012, we enrolled 3343 patients from 25 centers in 14 countries and followed them for 2 years to assess mortality, congestive heart failure, stroke or transient ischemic attack, recurrent acute rheumatic fever, and infective endocarditis. Results: Vital status at 24 months was known for 2960 (88.5%) patients. Two-thirds were female. Although patients were young (median age, 28 years; interquartile range, 18-40), the 2-year case fatality rate was high (500 deaths, 16.9%). Mortality rate was 116.3/1000 patient-years in the first year and 65.4/1000 patient-years in the second year. Median age at death was 28.7 years. Independent predictors of death were severe valve disease (hazard ratio [HR], 2.36; 95% confidence interval [CI], 1.80-3.11), congestive heart failure (HR, 2.16; 95% CI, 1.70-2.72), New York Heart Association functional class III/IV (HR, 1.67; 95% CI, 1.32-2.10), atrial fibrillation (HR, 1.40; 95% CI, 1.10-1.78), and older age (HR, 1.02; 95% CI, 1.01-1.02 per year increase) at enrollment. Postprimary education (HR, 0.67; 95% CI, 0.54-0.85) and female sex (HR, 0.65; 95% CI, 0.52-0.80) were associated with lower risk of death. Two hundred and four (6.9%) patients had new congestive heart failure (incidence, 38.42/1000 patient-years), 46 (1.6%) had a stroke or transient ischemic attack (8.45/1000 patient-years), 19 (0.6%) had recurrent acute rheumatic fever (3.49/1000 patient-years), and 20 (0.7%) had infective endocarditis (3.65/1000 patient-years). Previous stroke and older age were independent predictors of stroke/transient ischemic attack or systemic embolism. Patients from low-and lower-middle-income countries had significantly higher age-and sex-adjusted mortality than patients from upper-middle-income countries. Valve surgery was significantly more common in upper-middle-income than in lower-middle-or low-income countries. Conclusions: Patients with clinical rheumatic heart disease have high mortality and morbidity despite being young; those from low-and lower-middle-income countries had a poorer prognosis associated with advanced disease and low education. Programs focused on early detection and the treatment of clinical rheumatic heart disease are required to improve outcomes.
KW - Developing
KW - countries
KW - heart
KW - morbidity
KW - mortality
KW - outcome assessment
KW - patient
KW - rheumatic heart disease
KW - valves
UR - http://www.scopus.com/inward/record.url?scp=84991465866&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.116.024769
DO - 10.1161/CIRCULATIONAHA.116.024769
M3 - Article
C2 - 27702773
AN - SCOPUS:84991465866
SN - 0009-7322
VL - 134
SP - 1456
EP - 1466
JO - Circulation
JF - Circulation
IS - 19
ER -